ReviewFrontiers in immunology2023
Novel potential therapeutic targets of alopecia areata.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- The Role of Tissue Resident Memory Cells in Immunodermatological Disorders.International journal of dermatology · 2026Review
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata.Journal of nanobiotechnology · 2026Article
- Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Clinical Efficacy of Composite Autologous Chylated Fat and Concentrated Growth Factors for Treating Postinjection Alopecia After Facial Fillers: A Single-Center Retrospective Study.Journal of cosmetic dermatology · 2025Article
- Sexual Dysfunction in Alopecia Areata: A Systematic Review.Journal of clinical medicine · 2025Review
- Evaluation of Olive Oil-Based Formulations Loaded with Baricitinib for Topical Treatment of Alopecia Areata.Pharmaceutics · 2025Article
- Performance exploration of multi-gene panels of alopecia areata susceptibility and drug-binding targets.Frontiers in physiology · 2025Article
- Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis.Clinical, cosmetic and investigational dermatology · 2025Article
- Case Report: Severe ophiasis-pattern alopecia areata with concomitant atopic dermatitis in a 5-year-old boy successfully treated with dupilumab.Frontiers in pediatrics · 2025Article
- Mechanism of PPARα agonist in alopecia areata.American journal of translational research · 2025Article
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment.Frontiers in immunology · 2025Review
- Complete Blood Collection-based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-sectional Study.Acta dermato-venereologica · 2024Article
- Improvement of androgenic alopecia by extracellular vesicles secreted from hyaluronic acid-stimulated induced mesenchymal stem cells.Stem cell research & therapy · 2024Article
- Interleukin-33 links asthma to alopecia areata: Mendelian randomization and mediation analysis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Reprofiling synthetic glucocorticoid-induced leucine zipper fusion peptide as a novel and effective hair growth promoter.Archives of dermatological research · 2024Article
- Dissecting hair breakage in alopecia areata: the central role of dysregulated cysteine homeostasis.Amino acids · 2024Review
- Efficacy of probiotics in hair growth and dandruff control: A systematic review and meta-analysis.Heliyon · 2024Review
- Autophagy Dysfunction: The Kernel of Hair Loss?Clinical, cosmetic and investigational dermatology · 2024Review
- Enhancing hair regeneration: Recent progress in tailoring nanostructured lipid carriers through surface modification strategies.ADMET & DMPK · 2024Review
- Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is a non-scarring hair loss disorder caused by autoimmunity. The immune collapse of the hair follicle, where interferon-gamma (IFN-γ) and CD8+ T cells accumulate, is a key factor in AA. However, the exact functional mechanism remains unclear. Therefore, AA treatment has poor efficacy maintenance and high relapse rate after drug withdrawal. Recent studies show that immune-related cells and molecules affect AA. These cells communicate through autocrine and paracrine signals. Various cytokines, chemokines and growth factors mediate this crosstalk. In addition, adipose-derived stem cells (ADSCs), gut microbiota, hair follicle melanocytes, non-coding RNAs and specific regulatory factors have crucial roles in intercellular communication without a clear cause, suggesting potential new targets for AA therapy. This review discusses the latest research on the possible pathogenesis and therapeutic targets of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.